Involvement of prostaglandins in vasopressin stimulation of the human uterus.
The involvement of prostaglandins (PG) in the vasopressin (VP) action on the human uterus was investigated in healthy women during three menstruations. Intrauterine pressure was recorded and total pressure area measured. Repeated plasma samples were taken for estimations of arginine(A)- and lysine(L)-VP, 15-keto-13,14-dihydro-PGF2 alpha and 11-ketotetranor PGF metabolites. During the first menstruation LVP was infused in a dose of 0.08 micrograms/min. During the second menstruation the infusion of LVP was repeated with the same dose, but 70 min before infusion the women received an oral dose of 500 mg of naproxen. During the third menstruation PGF2 alpha was administered intravenously in a dose of 25 micrograms/min. LVP infusion per se caused a significant increase in uterine activity and plasma levels of LVP and PG metabolites. When the women were pretreated with naproxen practically the same uterine activity was induced and closely similar plasma levels of LVP were obtained, but the levels of PG metabolites decreased significantly in comparison with the first series of experiments. Infusion of PGF2 alpha caused an increase in uterine activity but no change in the plasma levels of AVP. The results indicate that uterine stimulation with VP is possible without an obligatory last step of PG synthesis and release. The results also support the concept that an elevated VP level in primary dysmenorrhoea may be of aetiological importance and is not just released as a 'stress'-hormone because of the dysmenorrhoeic pain.
D000328:Adult; D001127:Arginine Vasopressin / Q000097:blood; D015237:Dinoprost / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008236:Lypressin / Q000097:blood / Q000494:pharmacology; D008598:Menstruation; D009288:Naproxen / Q000494:pharmacology; D011312:Pressure; D011453:Prostaglandins / Q000502:physiology*; D011460:Prostaglandins F / Q000097:blood / Q000494:pharmacology; D014599:Uterus / Q000187:drug effects / Q000502:physiology*; D014667:Vasopressins / Q000502:physiology*
D011453:Prostaglandins; D011460:Prostaglandins F; D014667:Vasopressins; D001127:Arginine Vasopressin; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; C019171:prostaglandin F-main urinary metabolite; D008236:Lypressin; D009288:Naproxen; D015237:Dinoprost